Thomas W. Davis

2.9k total citations
54 papers, 2.0k citations indexed

About

Thomas W. Davis is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Thomas W. Davis has authored 54 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 18 papers in Oncology and 11 papers in Cancer Research. Recurrent topics in Thomas W. Davis's work include Cancer-related Molecular Pathways (8 papers), Cancer, Hypoxia, and Metabolism (8 papers) and RNA modifications and cancer (7 papers). Thomas W. Davis is often cited by papers focused on Cancer-related Molecular Pathways (8 papers), Cancer, Hypoxia, and Metabolism (8 papers) and RNA modifications and cancer (7 papers). Thomas W. Davis collaborates with scholars based in United States, United Kingdom and Japan. Thomas W. Davis's co-authors include Jaime L. Masferrer, Ben S. Zweifel, Liangxian Cao, David A. Boothman, Timothy J. Kinsella, Richard Ornberg, Ovidiu C. Trifan, Marla Weetall, Young‐Choon Moon and Nadiya Sydorenko and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Thomas W. Davis

51 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas W. Davis United States 24 1.1k 634 457 301 261 54 2.0k
Ken‐ichi Kozaki Japan 21 906 0.8× 312 0.5× 357 0.8× 209 0.7× 82 0.3× 34 1.5k
Wolfram C. M. Dempke Germany 20 727 0.6× 727 1.1× 258 0.6× 217 0.7× 136 0.5× 48 1.8k
Andrea Gsur Austria 27 1.2k 1.1× 648 1.0× 262 0.6× 72 0.2× 221 0.8× 76 2.1k
Alexandre Puissant France 31 2.0k 1.8× 454 0.7× 429 0.9× 129 0.4× 127 0.5× 59 3.1k
Lin‐Hung Wei Taiwan 26 1.7k 1.5× 1.1k 1.7× 609 1.3× 116 0.4× 176 0.7× 67 3.0k
Guy Makin United Kingdom 23 969 0.9× 537 0.8× 375 0.8× 56 0.2× 260 1.0× 49 1.8k
D. Lee Gorden United States 24 623 0.5× 538 0.8× 300 0.7× 177 0.6× 106 0.4× 38 1.9k
Wei Cui United States 22 939 0.8× 519 0.8× 356 0.8× 76 0.3× 213 0.8× 86 1.8k
Adriana Zingone United States 23 945 0.8× 430 0.7× 311 0.7× 63 0.2× 101 0.4× 59 1.8k
Mathias T. Rosenfeldt Germany 20 1.4k 1.2× 505 0.8× 613 1.3× 135 0.4× 88 0.3× 42 2.2k

Countries citing papers authored by Thomas W. Davis

Since Specialization
Citations

This map shows the geographic impact of Thomas W. Davis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas W. Davis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas W. Davis more than expected).

Fields of papers citing papers by Thomas W. Davis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas W. Davis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas W. Davis. The network helps show where Thomas W. Davis may publish in the future.

Co-authorship network of co-authors of Thomas W. Davis

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas W. Davis. A scholar is included among the top collaborators of Thomas W. Davis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas W. Davis. Thomas W. Davis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Davis, Thomas W., et al.. (2025). Clinician perspectives on designing and implementing a hereditary cancer transition clinic. Hereditary Cancer in Clinical Practice. 23(1). 2–2.
2.
3.
Steinway, Caren, et al.. (2024). Medicaid long‐term services and supports and caregiving needs of caregivers of individuals with intellectual and developmental disabilities. Journal of Applied Research in Intellectual Disabilities. 37(5). e13289–e13289.
4.
Alimbetov, Dauren, et al.. (2023). Small molecule targeting of the p38/Mk2 stress signaling pathways to improve cancer treatment. BMC Cancer. 23(1). 895–895. 4 indexed citations
5.
Steinway, Caren, et al.. (2023). Caregiver support, burden, and long‐term planning among caregivers of individuals with intellectual and developmental disabilities: A cross‐sectional study. Journal of Applied Research in Intellectual Disabilities. 36(6). 1229–1240. 3 indexed citations
6.
Baiazitov, Ramil, Hongyan Qi, Liangxian Cao, et al.. (2022). SAR studies toward discovery of emvododstat (PTC299), a potent dihydroorotate dehydrogenase (DHODH) inhibitor. European Journal of Medicinal Chemistry. 244. 114826–114826. 3 indexed citations
7.
Davis, Thomas W., et al.. (2020). Atrial Fibrillation with E-Cigarette Use in an Otherwise Healthy Adolescent Male. PEDIATRICS. 146. 312–313. 1 indexed citations
8.
Davis, Thomas W., et al.. (2020). Evaluation of the Validity of the Pediatric Sequential Organ Failure Assessment Score in Critically Ill Children. PEDIATRICS. 146. 159–161. 1 indexed citations
9.
Dey, Anindya, Xunhao Xiong, Shailendra Kumar Dhar Dwivedi, et al.. (2017). Evaluating the Mechanism and Therapeutic Potential of PTC-028, a Novel Inhibitor of BMI-1 Function in Ovarian Cancer. Molecular Cancer Therapeutics. 17(1). 39–49. 31 indexed citations
10.
Davis, Thomas W., et al.. (2017). Preparing for Transition of Youth with Special Health Care Needs. Current problems in pediatric and adolescent health care. 47(8). 200–207. 3 indexed citations
11.
Friesen, Westley J., Christopher R. Trotta, Jin Zhuo, et al.. (2017). The nucleoside analog clitocine is a potent and efficacious readthrough agent. RNA. 23(4). 567–577. 36 indexed citations
12.
Bansal, Nitu, Monica Bartucci, Shamila Yusuff, et al.. (2016). BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer. Clinical Cancer Research. 22(24). 6176–6191. 49 indexed citations
13.
Cao, Liangxian, et al.. (2011). BMI1 as a novel target for drug discovery in cancer. Journal of Cellular Biochemistry. 112(10). 2729–2741. 117 indexed citations
14.
Peltz, Stuart W., Ellen Welch, Christopher R. Trotta, Thomas W. Davis, & Allan Jacobson. (2009). Targeting post-transcriptional control for drug discovery. RNA Biology. 6(3). 329–334. 11 indexed citations
15.
Davis, Thomas W., Duncan M. Baird, Michele F. Haughton, Christopher J. Jones, & David Kipling. (2005). Prevention of Accelerated Cell Aging in Werner Syndrome Using a p38 Mitogen-Activated Protein Kinase Inhibitor. The Journals of Gerontology Series A. 60(11). 1386–1393. 74 indexed citations
16.
Davis, Thomas W., et al.. (2004). Inhibition of Cyclooxygenase-2 by Celecoxib Reverses Tumor-Induced Wasting. Journal of Pharmacology and Experimental Therapeutics. 308(3). 929–934. 68 indexed citations
17.
Davis, Thomas W., Nancy Hunter, Ovidiu C. Trifan, Luka Milas, & Jaime L. Masferrer. (2003). COX-2 Inhibitors as Radiosensitizing Agents for Cancer Therapy. American Journal of Clinical Oncology. 26(Supplement 2). S58–S61. 37 indexed citations
18.
Zweifel, Ben S., Thomas W. Davis, Richard Ornberg, & Jaime L. Masferrer. (2002). Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.. PubMed. 62(22). 6706–11. 125 indexed citations
19.
Davis, Thomas W., Erwin R. Boghaert, Carla Guthridge, Marion R. Steiner, & Stephen G. Zimmer. (1997). The Effects of Group II Phospholipase A2 on Ras-Induced Metastasis. Advances in experimental medicine and biology. 400A. 9–17. 1 indexed citations
20.
Boothman, David A., Thomas W. Davis, & Walter M. Sahijdak. (1994). Enhanced expression of thymidine kinase in human cells following ionizing radiation. International Journal of Radiation Oncology*Biology*Physics. 30(2). 391–398. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ken‐ichi Kozaki Breakdown of academic impact, for papers by Wolfram C. M. Dempke Breakdown of academic impact, for papers by Andrea Gsur Breakdown of academic impact, for papers by Alexandre Puissant Breakdown of academic impact, for papers by Lin‐Hung Wei Breakdown of academic impact, for papers by Guy Makin Breakdown of academic impact, for papers by D. Lee Gorden Breakdown of academic impact, for papers by Wei Cui Breakdown of academic impact, for papers by Adriana Zingone Breakdown of academic impact, for papers by Mathias T. Rosenfeldt
Rankless by CCL
2026